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Appendix 1: European studies carried out investigating the effect of drug safety warnings on antipsychotic use in older people. 
Author, 






with and without 
dementia 
All APs, APs by class and 
olanzapine and 
risperidone individually 
from 2003 to 2011 
Monthly prevalence of AP use as a 
function of the 2004 and 2009 
EMA warnings 
-The monthly use of all APs decreased steadily from 2003-2011 from 16-11% and did not appear to be associated 
with the warnings. 
-Atypical APs decreased from 12% in 2003 to 5% in 2011 but the trend was already decreasing before the warning; 
after the 2009 warning this decrease stopped. 
-Conventional AP use increased from 3% in 2003 to 5% in 2011. Minimal changes in drug utilization were seen after 
both warnings. 
-Olanzapine use remained stable at 0.5% from 2003-2011; no change in trend was seen after the warnings. 
-Risperidone use increased from 2% in 2003 to 4% in 2011; use of this drug increased slightly after the 2004 







All APs and APs by class 
from 2004 to 2009 
Change in yearly prevalence of AP 
use, number of AP packages and 
DDD per person per year as a 
function of the 2004 drug safety 
mails in Germany, the 2005 FDA 
safety warning on atypical AP use 
and the 2008 FDA/EMA warning 
on conventional AP use. 
-The yearly prevalence of any AP use changed minimally after the 2004 warning (from 35% before to 34% the year 
after). Similarly small changes were seen after the 2005 warning, where the prevalence of use changed from 34% to 
32% in the year after. No changes were seen after the 2008 warning, with the prevalence remaining stable at 32%. 
-The trend for conventional AP use was very similar to that of AP use overall, starting at 27% before to 26% after 
the 2004 warning, decreasing to 23% after the 2005 warning. The prevalence of use remained at 23 % before and 
after the 2008 warning. 












Quarterly prevalence of oral AP 
prescribing, initiation and 
discontinuation; prescription of 
hypnotics, anxiolytics or 
antidepressants 
-In 2001 15% of dementia patients were prescribed any oral AP, increasing to 23% just before the 2004 warning. 
Levels dropped back to 15% after the 2004 warning. The 2009 warning was associated with a reduction from 17% to 
14% after the 2009 warning. 
-Risperidone use decreased from 12% before the 2004 warning to 4% shortly after. No decrease was seen after the 
2009 warning. 
-Olanzapine use decreased from 3% before the 2004 warning to 1% shortly after. No change was seen after the 2009 
warning. 
-Quetiapine use increased steadily after the 2004 warning, up to a peak of 8% just before the 2009 warning. There 
was a short-term decrease in quetiapine use after the 2009 warning which decreased back to pre-warning levels 















individually from 2002 to 
2008 
Number of AP prescriptions per 
person and gap between AP 
prescriptions as a function of the 
2004 EMA warning and the 2006 
AIFA warning; yearly prevalence 
of AP use, probability of 
continuing antipsychotic 
treatment. 
-The yearly prevalence of AP use decreased from 23% before the 2004 warning to 17% a year after the 2004 
warning. AP use decreased from 17% to 16% after the 2006 warning but levels rose back up to 17% 1 year later. 
-Atypical AP use decreased from 20% before the 2004 warning to 16% in the year after. Following the 2006 
warning, atypical AP use decreased from 16% to 14% within a year but rose back to 15% the year later. 
-Conventional AP use decreased slightly following the 2004 warning, from 4% to 3% over 2 years. Levels rose to 
almost 5% after the second warning in 2006. 
-Olanzapine use decreased from 5% to 3% within a year of the 2004 warning but no change was seen after the 2006 
warning. 
-Risperidone use was very similar to olanzapine but levels decreased by approximately 1% after the 2006 warning. 
-Quetiapine use was already increasing before the 2004 warning and continued to do so after, albeit at a lower rate 
(from 9% before to 11% a year after). After the 2006 warning, there was a short-term decreased in use from 13% to 
10% after a year, which rose to 12% a year later. 
-The use of haloperidol did not seem to change with the warnings, the prevalence of which remained below 2% from 
until 2007, increasing to 3% in 2008. 
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persons and elderly 
persons with 
dementia 








elderly persons with 
dementia from 2000 to 
2005. 
One-year and monthly prevalence 
of AP use as a function of the 
2004 MHRA warning and the 
2005 FDA warning. 
-The monthly prevalence of conventional AP use increased from 12% to 14% after the 2004 warning and did not 
appear to change after the 2005 warning. 
- The monthly prevalence of atypical AP use decreased from 8% to 6% after the 2004 warning but started increasing 











and younger adults 
Risperidone and 
olanzapine use (stratified 
by strength) from 2000 to 
2006 
Monthly prevalence of risperidone 
and olanzapine use in DDD as a 
function of three warnings issued 
by the Spanish drug agency: 
March and May 2004 (considered 
as one warning) and February 
2005 
-Low-strength risperidone use among pensioners decreased from 95,000 DDDs per month before the 2004 warnings 
to 90,000 after. This dropped to 65,000 DDDs after the 2005 warning. No change was seen for high-dose risperidone 
use among pensioners which increased throughout the study. 
-Low-strength olanzapine use among pensioners decreased from 15,000 DDDs before the 2004 warnings to 9,000 
DDDs within a year. No change was seen after the 2005 warning. High-dose olanzapine use increased steadily 
throughout the study. 
Abbreviations: ACheEI: acetylcholinesterase inhibitor; AIFA: Agenzia Italiana del Farmaco (Italian Drug Agency); EGB: Echantillon Généraliste de Bénéficiaires; EMA: European 
Medicines Agency; DDD: defined daily dose; FDA: Food and Drug Administration; GEK: Gmünder Ersatz Kasse, a German nationwide health insurance company database; HSD-CSD-LPD:  
Health Search Database - Cegedim Strategic Data, Longitudinal Patient Database; MHRA: Medicines and Healthcare Products Regulatory Agency; PCCIU: Primary Care Clinical Information 
Unit. 
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Appendix 2: Dementia diagnoses in THIN (UK) and HSD (Italy). 
Dementia Read codes 
 
A410.00,  A411.00, E00..00, E00..11, E00..12, E000.00, E001.00, E001000, E001100, E001200, E001300, E001z00, E002.00, E002000, E002100, E002z00, E003.00, E004.00, E004.11, 
E004000, E004100, E004200, E004300, E004z00, E012.00, E012.11, E012000, Eu00.00, Eu00000, Eu00011, Eu00012, Eu00013, Eu00100, Eu00111, Eu00112, Eu00113, Eu00200, 
Eu00z00, Eu00z11, Eu01000, Eu01200, Eu01300, Eu01y00,Eu01z00, Eu02000, Eu02100, Eu02400, Eu02z00, Eu02z11, Eu02z12, Eu02z13, Eu02z14, Eu02z15, Eu02z16, 
F110.00,F111.00, F116.00, F11x700, F21y200, F21y211, Fyu3000 
 
ICD9-CM dementia codes 
 
290, 290.0, 290.1, 290.10, 290.11, 290.12, 290.13, 290.2, 290.21, 
290.20, 290.3, 290.4, 290.40, 290.41, 290.42, 290.43, 290.8, 290.9, 294.1, 331.0, 331.1 




Appendix 3: Multilex codes for antipsychotic drugs in THIN (UK). All antipsychotics have the BNF code ‘4020100’.  
 
Drug name Multilex Code 
Amisulpride 91077998, 91425998, 88383997, 88383996, 88383998, 90209998, 86433998, 91083998, 94545990, 94845990, 88387997, 94544990, 94844990, 88387996, 88387998, 94846990 
Aripiprazole 85834998, 87450998, 85833998, 87449998, 85832998, 87448998, 87089998, 83903998, 85835998, 85837998, 85836998, 87453998, 87452998, 87451998, 87090998 
Benperidol 82225998, 88885998, 95979998, 95980998 
Chlorpromazine 
97871998, 82892998, 96689996, 97879998, 95200992, 97877998, 97880998, 97134992, 96689998, 97880997, 93242998, 97132992, 96689997, 97880996, 97129992, 96614992, 
94111992, 94821992, 96102992, 94107992, 98186990, 96690998, 96691996, 99007990, 93587998, 93593998, 98062989, 95687990, 96690996, 98062990, 96690997, 96691997, 
96919989, 97236988, 98192989, 96691998, 94761998, 95365990, 97236990, 98189990, 98192988, 94761997, 95364990, 96919990, 97236989, 98192990, 99010990 
Chlorprothixene 96686997 
Clozapine 87019998,87340998, 93596997, 82800998, 87020998, 87341998, 93596998, 82802998, 82799998, 93595997, 82801998, 93595998, 82803998 
Dartalan (Thiopropazate) 94891992 
Droperidol 97343998, 97343997, 93674998, 97334992, 93675998, 96303997, 96303998 
Flupenthixol 98766998, 98766997, 99775998, 97516998, 99776998, 86421998, 86420998, 85613998, 96502997, 96502998, 86422998, 96502996, 85614998, 94879998, 86423998, 96503998 
Fluphenazine 
85300998, 96342992, 85295998, 98759998, 85294998, 85299998, 85298998, 99414998, 93032992, 96498997, 96498998, 85296998, 85303998, 85302998, 96286990, 96742990, 
85297998, 85301998, 99408998, 96500998, 99411998, 99411997, 99411996, 97466992, 96501998, 96501997, 96501996 
Fluspirilene 99189998, 96494998 
Haldoperidol 
95086992, 96265992, 97946997, 96307992, 97344997, 97346997, 97945998, 97345997, 96242998, 97945997, 96758992, 97944997, 96242997, 97346996, 97945996, 97568992, 
97946998, 96244998, 97344998, 97346998, 97946996, 83786998, 97944998, 96245997, 96245998, 96246998, 93695997, 83787998, 93695998, 98155990, 96247997, 96248996, 
98131989, 98625989, 92815996, 96247998, 98625990, 91921998, 92815998, 98080990, 96247996, 98625988, 92815997, 96115990, 96249997, 97135989, 98131990, 8360988, 
98544990, 96248998, 96248997, 96249998, 97135990, 96249996, 96889990, 98154990, 98544988 
Levomepromazine 95918998, 98853997, 98853998, 95919998, 95919997, 82709998, 87504998, 87505998 
Loxapine 94007998, 94007997, 94007996, 94006998, 94006997, 94006996 
Olanzapine 
91618997, 89569996, 91364998, 97433998, 90664998, 86324998, 85376998, 91618998, 89569998, 89569997, 90659996, 97995998, 86325998, 90659997, 87647998, 89567996, 
7111998, 90659998, 85377998, 89567998, 89567997 
Paliperidone 84524998, 84523998, 84527998, 84526998, 84525998 
Pericyazine 83019998, 99362997, 98865998, 97878992, 83020998, 99362998, 99362996, 95576998, 95577997, 95577998, 95577996 
Perphenazine 99651998, 99651997, 98587998, 97877992, 94164992, 95575998, 97786998, 97786997, 95575997, 95575996 
Pimozide 97342996, 97342998, 97342997, 95516996, 95516998, 95516997 
Pipotiazine 85409998, 98622998, 85410998, 85411998, 85413998, 95503998 
Promazine 
99117998, 98783998, 96750992, 93708997, 93708998, 97406989, 95385998, 95386998, 95386996, 95386997, 98063990, 95385997, 98063989, 93476998, 98786996, 93477998, 
98786998, 99093990, 93477997, 98786997, 99093988 
Quetiapine 
88734996, 81923998, 88733997, 83492998, 88733998, 88734998, 88734997, 83491998, 87907998, 83490998, 83493998, 81924998, 83995998, 83994998, 83993998, 83996998, 
82773998, 82772998, 88737998, 88737996, 88736997, 88736998, 88737997, 87908998 
Risperidone 
86983998, 92023998, 90395998, 99649998, 93240997, 91676998, 92107998, 99649997, 92089998, 85039998, 96914992, 99649996, 85038998, 93240998, 89908998, 93240996,  
99637997, 91374998, 90396998, 85042998, 85040998, 86984998, 92491990, 88164998, 88163998, 95519998, 91968998, 92957990, 98585998, 98585997, 98585996, 92953990, 
99637998, 99637996 
Sertindole 89809997, 89809996, 89809998, 89812997, 89812996, 89811998, 89812998 




Thioproperazine 96492992, 98173992 
Thioridazine 
99436998, 98899997, 99437998, 99437997, 98899998, 98899996, 99437996, 96570992, 92821997, 95173996, 95174996, 95174997, 95173997, 98403989, 95173998, 98003989, 
98403990, 92821998, 95174998, 98404988, 95175998, 95175997, 97715990, 98003990, 98404990, 95175996, 97715989, 98003988, 98404989 
Trifluoperazine 
99108996, 99107998, 95607992, 99109998, 99107997, 99109996, 99108997, 98203992, 99109997, 98206992, 95119998, 99108998, 95118997, 95119996, 95118998, 92623996, 
95118996, 92623997, 92623998, 98052989, 98400990, 95119997, 98052990, 87435998 
Trifluperidol 95116997, 98204992, 95116998, 95117998, 95117997 
Zotepine 98190996, 98190998, 98190997, 99337996, 99337998, 99337997 
Zuclopenthix Decanoate 85607998, 95071998, 85609998, 96628998, 96628997, 98767998 
Zuclopenthixol Acetate 93519998, 86332998, 86334998, 86333998, 86335998, 93520998 







Appendix 4: Crude prevalence of antipsychotic use in patients under 65 years in the UK (THIN) per quarter year during the study period from the 1st quarter of 2000 to the 1st 
quarter of 2012, with main warnings labelled. 
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Appendix 5: Crude prevalence of antipsychotic use in patients under 65 years per quarter year in Italy (HSD-CSD-LPD) from the 1st quarter of 2000 to the 1st quarter of 2012, 
with main warnings labelled. 
 































































































































































































































































































































































































































































































































































































































Appendix 6: Crude prevalence of antipsychotic use in patients ≥65 years (irrespective of dementia diagnosis) per quarter year in the UK (THIN) from the 1st quarter of 2000 to the 
1st quarter of 2012, with main warnings labelled. 
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EMA warning  
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Appendix 7: Crude prevalence of antipsychotic use in patients ≥65 years (irrespective of dementia diagnosis) per quarter year in Italy (HSD-CSD-LPD) from the 1st quarter of 2000 
to the 1st quarter of 2012, with main warnings labelled. 
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11 
 
Appendix 8: Quarterly prevalence rates of olanzapine use in dementia patients ≥65 years old in the UK (THIN- left panel) and Italy (HSD-CSD LPD- right panel) from the first 
quarter of 2000 to the first quarter of 2012, with main warnings labelled. 
 







































































Appendix 9: Quarterly prevalence of risperidone use in dementia patients ≥65 years old in the UK (THIN- left panel) and Italy (HSD-CSD LPD -right panel) from the first quarter 
of 2000 to the first quarter of 2012, with main warnings labelled. 
 












































































Appendix 10: Quarterly prevalence of quetiapine use in dementia patients ≥65 years old in the UK (THIN- left panel) and Italy (HSD-CSD LPD- right panel) from the first quarter 
of 2000 to the first quarter of 2012, with main warnings labelled. 
 



















































































































































































EMA warning  
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Appendix 11: Quarterly prevalence of haloperidol use in dementia patients ≥65 years old in the UK (THIN- left panel) and Italy (HSD-CSD LPD- right panel) from the first quarter 
of 2000 to the first quarter of 2012, with main warnings labelled. 
 






















































































































































































Appendix 11: Prevalence of antipsychotics use in patients 65 and over with dementia in the UK (THIN) at 3, 6 and 12 months before and after the warnings. 
Antipsychotic 
Time window before and 
after warnings 
Warning occurrence  
 
Prevalence of AP use before 
the warning (%) 
Prevalence of AP use after 
the warning (%) 






1st quarter 2004 1.8 1.5 <0.001* 
 1st quarter 2009 1.1 1.1 0.893 
6 months 
 1st quarter 2004 1.1 1.3 <0.001* 
 1st quarter 2009 1.1 1.1 0.756 
12 months 
1st quarter 2004 1.6 1.2 <0.001* 
1st quarter 2009 1.1 1.1 0.573 
Quetiapine 
3 months 
1st quarter 2004 0.8 1.4 <0.001* 
1st quarter 2009 6.6 6.5 0.612 
6 months 
1st quarter 2004 0.8 1.6 <0.001* 
1st quarter 2009 6.5 6.6 0.457 
12 months 
1st quarter 2004 0.7 2.0 <0.001* 
1st quarter 2009 6.2 6.6 <0.001* 
Risperidone 
3 months 
1st quarter 2004 5.2 3.4 <0.001* 
1st quarter 2009 1.5 1.5 0.939 
6 months 
1st quarter 2004 5.1 2.9 <0.001* 
1st quarter 2009 1.5 1.5 0.529 
12 months 
1st quarter 2004 4.9 2.4 <0.001* 
1st quarter 2009 1.5 1.6 0.262 
Haloperidol 
3 months 
1st quarter 2004 0.9 1.5 <0.001* 
1st quarter 2009 2.0 1.8 0.100 
6 months 
1st quarter 2004 0.9 1.6 <0.001* 
1st quarter 2009 2.0 1.8 0.061 
12 months 
1st quarter 2004 0.9 1.7 <0.001* 
1st quarter 2009 2.0 1.8 0.004* 




Appendix 12: Prevalence of antipsychotic use in patients 65 and over with dementia in Italy (HSD-CSD-LPD) at 3, 6 and 12 months before and after the warnings. 
Antipsychotic 
Time window before and after 
warnings 
Warning occurrence  
Prevalence of AP use  
before warning (%) 
Prevalence of AP use after 
warning (%) 






1st quarter 2004 1.7 1.0 <0.001* 
2nd quarter 2009 1.6 1.7 0.460 
6 months 
1st quarter 2004 1.6 0.9 <0.001* 
2nd quarter 2009 1.6 1.6 0.872 
12 months 
1st quarter 2004 1.6 0.9 <0.001* 
2nd quarter 2009 1.5 1.6 0.808 
Quetiapine 
3 months 
1st quarter 2004 1.3 2.2 <0.001* 
2nd quarter 2009 7.7 837 0.195 
6 months 
1st quarter 2004 1.1 2.2 <0.001* 
2nd quarter 2009 7.3 8.6 <0.001* 
12 months 
1st quarter 2004 1.0 2.4 <0.001 
2nd quarter 2009 6.5 9.3 <0.001* 
Risperidone 
3 months 
1st quarter 2004 1.8 1.3 0.005* 
2nd quarter 2009 1.0 1.1 0.925 
6 months 
1st quarter 2004 1.7 1.1 <0.001* 
2nd quarter 2009 1.1 1.1 0.952 
12 months 
1st quarter 2004 1.8 1.0 <0.001* 
2nd quarter 2009 1.1 1.1 0.996 
Haloperidol 
3 months 
1st quarter 2004 2.3 2.7 0.066 
2nd quarter 2009 4.7 4.4 0.417 
6 months 
1st quarter 2004 2.1 2.7 <0.001* 
2nd quarter 2009 4.5 4.5 0.980 
12 months 
1st quarter 2004 2.1 3.0 <0.001* 
2nd quarter 2009 4.3 4.9 0.003* 








Start of study (1st quarter 2000) to 
first EMA/MHRA warning (1st 
quarter 2004) 
First EMA/MHRA warning (1st 
quarter 2004 to second EMA 
warning (3rd quarter 2005) 
Second EMA warning (3rd quarter 
2005) to second MHRA warning 
(1st quarter 2009) 
Second MHRA warning (1st 
quarter 2009) to end of study (1st 
quarter 2012) 
Median changes in prevalence 
(%) per quarter year 
All APs 0.0044% (-0.018, 0.241%)* 0.0016% (-0.005, 0.196%)* 0.0013% (-0.005, 0.337%)* -0.0017% (-0.197, 0.002%)* 
Conventional APs 0.0042% (-0.228, 0.241%)* 0.0020% (-0.005, 0.196%)* 0.0007% (-0.019, 0.330%) -0.0019% (-0.197, 0.002%)* 
Atypical APs 0.0044% (-0.220, 0.513%)* 0.0024% (-0.005, 0.196%) 0.0013% (-0.019, 0.350%)* -0.0041% (-0.197, 0.002%)* 
Olanzapine 0.0055% (-0.220, 0.513%)* 0.0020% (-0.083, 0.196%)* 0.0039% (-0.019, 0.350%) -0.0071% (-0.195, 0.002%)* 
Quetiapine 0.0071% (-0.220, 0.513%)* 0.0024% (-0.083, 0.374%)* 0.0040% (-0.019, 0.352%) -0.0078% (-0.195, 0.002%)* 
Risperidone 0.0093% (-0.211, 0.470%)* 0.0020% (-0.475, 0.374%)* 0.0039% (-0.019, 0.352%) -0.0071% (-0.195, 0.117%)* 
Haloperidol 0.0110% (-0.211, 0.470%)* 0.0024% (-0.402, 0.325%)* 0.0040% (-0.019, 0.352%)* -0.0078% (-0.195, 0.117%)* 
*The corresponding log odds ratio change of AP use for each unitary increase of a quarter year (test for linear trend) was statistically significant. The percentiles reported in brackets cannot be 




Appendix 14: Estimated annual prevalence rate in each time window in elderly people in the UK with dementia.  
 
  
Start of study (1st quarter 2000) to 
first EMA/MHRA warning (1st 
quarter 2004) 
First EMA/MHRA warning (1st 
quarter 2004) to second EMA 
warning (3rd quarter 2005) 
Second EMA warning (3rd quarter 
2005) to second MHRA warning 
(1st quarter 2009) 
Second MHRA warning (1st 
quarter 2009) to end of study (1st 
quarter 2012) 
Annual  prevalence 
rate in  person-years (%) 
All APs 4.5% 8.4% 7.1% 8.7% 
Conventional APs 2.2% 3.6% 2.6% 2.5% 
Atypical APs 2.4% 5.2% 4.8% 6.5% 
Olanzapine 0.5% 1.1% 0.5% 0.6% 
Quetiapine 0.2% 1.6% 2.8% 3.8% 
Risperidone 0.0% 0.0% 0.1% 0.2% 
Haloperidol 1.7% 2.2% 0.9% 1.3% 
















Start of study (1st quarter 2000) 
to EMA warning  (1st quarter 
2004) 
EMA warning  (1st quarter 
2004) to AIFA warning (3rd 
quarter 2005) 
AIFA warning (3rd quarter 2005) to 
EMA/AIFA warning (4th quarter 
2008) 
EMA/AIFA warning (4th quarter 2008) 
to AIFA warning (3rd quarter 2009) 
AIFA warning (3rd quarter 2009) 
to end of study (4th quarter 2012) 
Median changes in 
prevalence (%) per 
quarter year 
 
All APs 0.0009% (-0.017, 0.182%)* 0.0014% (-0.008, 0.398%)* 0.0015% (-0.004, 0.433%)* 0.0011% (-0.017, 0.115%) 0.0005% (-0.005, 1.118%)* 
Conventional APs 0.0008% (-0.017, 0.179%) 0.0015% (-0..008, 0.398%)* 0.0016% (-0.004, 0.423%)* 0.0011% (-0.023, 0.013%) 0.0005% (-0.005, 1.118%)* 
Atypical APs 0.0009% (-0.017, 0.198%)* 0.0015% (-0.008, 0.398%)* 0.0018% (-0.004, 0.423%)* 0.0011% (-0.023, 0.219%)* 0.0008% (-0.005, 1.089%)* 
Olanzapine 0.0010% (-0.017, 0.201%)* 0.0015% (-0.054, 0.386%)* 0.0019% (-0.004, 0.423%)* 0.0011% (-0.023, 0.219%) 0.0012% (-0.005, 1.089%)* 
Quetiapine 0.0012% (-0.017, 0.204%)* 0.0015% (-0.054, 0.386%)* 0.0022% (-0.004, 0.423%)* 0.0011% (-0.023, 0.366%)* 0.0017% (-0.005, 1.089%)* 
Risperidone 0.0014% (-0.017, 0.204%)* 0.0015% (-0.095, 0.386%)* 0.0019% (-0.004, 0.414%) 0.0012% (-0.023, 0.366%) 0.0020% (-0.005, 1.060%) 
Haloperidol 0.0017% (-0.017, 0.203%)* 0.0015% (-0.095, 0.386%)* 0.0022% (-0.004, 0.414%)* 0.0011% (-0.104, 0.366%) 0.0020% (-0.005, 1.060%)* 
*The corresponding log odds ratio change of AP use for each unitary increase of a quarter year (test for linear trend) was statistically significant. The percentiles reported in brackets cannot be 
interpreted as the conventional 95% confidence intervals. Abbreviations: AIFA- Agenzia Italiana del Farmaco; APs- antipsychotics; EMA- European Medicines Agency 
 
  
Appendix 16: Estimated annual prevalence rate in each time window in Italian elderly people with dementia.  
 
  
Start of study (1st quarter 2000) 
to EMA warning  (1st quarter 
2004) 
EMA warning  (1st quarter 
2004) to AIFA warning (3rd 
quarter 2005) 
AIFA warning (3rd quarter 2005) to 
EMA/AIFA warning (4th quarter 
2008) 
EMA/AIFA warning (4th quarter 2008) 
to AIFA warning (3rd quarter 2009) 
AIFA warning (3rd quarter 2009) 
to end of study (4th quarter 2012) 
Annual prevalence 
rate in  person-years 
(%) 
All APs 3.9% 8.1% 6.3% 21.9% 11.5% 
Conventional APs 2.4% 4.8% 3.7% 11.1% 5.7% 
Atypical APs 1.7% 3.7% 3.0% 12.4% 6.6% 
Olanzapine 0.3% 0.7% 0.4% 1.6% 0.7% 
Quetiapine 0.2% 1.7% 1.8% 8.6% 4.9% 
Risperidone 0.0% 0.0% 0.0% 0.0% 0.0% 
Haloperidol 0.5% 0.8% 0.4% 1.1% 0.5% 








Appendix 17: Prevalence of use of conventional and atypical antipsychotic use in patients ≥80 per quarter year in the UK (THIN) and Italy (HSD-CSD-LPD) year during the study 
period from the 1st quarter of 2000 to the 1st quarter of 2012. 
 
































































































































































































































































































































































































































































































































































































































Appendix 18: Yearly prevalence of dementia in THIN in persons aged ≥65 years old (UK).  
Year Numerator Denominator Prevalence of dementia (95% CI) 
2000 3,616 916,087 0.4 (0.39-0.41) 
2001 4,985 984,875 0.5 (0.49-0.51) 
2002 6,457 1,059,397 0.6 (0.59-0.61) 
2003 8,153 1,134,980 0.7 (0.68-0.72) 
2004 10,095 1,211,921 0.8 (0.78-0.82) 
2005 11,922 1,287,350 0.9 (0.88-0.92) 
2006 14,077 1,364,504 1 (0.98-1.02) 
2007 15,986 1,450,876 1.1 (1.08-1.12) 
2008 17,878 1,539,736 1.2 (1.18-1.22) 
2009 19,874 1,636,149 1.2 (1.18-1.22) 
2010 21,833 1,728,766 1.3 (1.28-1.32) 
2011 23,721 1,839,240 1.3 (1.28-1.32) 




Appendix 19: Yearly prevalence of dementia in HSD-CSD-LPD in persons aged ≥65 years old (Italy). 
Year Numerator Denominator Prevalence of dementia (95% CI) 
2000 1,558 639,586 0.2 (0.19-0.21) 
2001 2,180 721,107 0.3 (0.29-0.31) 
2001 2,841 811,929 0.3 (0.29-0.31) 
2003 3,335 871,157 0.4 (0.39-0.41) 
2004 3,849 895,588 0.4 (0.39-0.41) 
2005 4,348 907,515 0.5 (0.49-0.51) 
2006 4,727 923,875 0.5 (0.49-0.51) 
2007 5,032 938,065 0.5 (0.49-0.51) 
2008 5,281 940,408 0.6 (0.58- 0.62) 
2009 5,471 944,122 0.6 (0.58- 0.62) 
2010 5,718 948,496 0.6 (0.58-0.62) 
2011 5,519 944,784 0.6 (0.58-0.62) 
Abbreviation: 95% CI- 95% confidence intervals 
 
